91��Ƶ

Mumbai, January 8, 2025: Global pharma major 91��Ƶ Limited (91��Ƶ) today announced that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (U.S. FDA) for its Pithampur Unit-1 manufacturing facility that manufactures both APIs and finished products. The EIR was issued with an inspection classification of Voluntary Action Indicated (VAI) post the inspection of the facility from September 16 to September 27, 2024.

Nilesh Gupta, Managing Director, 91��Ƶ said, “We are pleased to receive the EIR from the US FDA for our Pithampur Unit-1 facility with a satisfactory VAI classification. This reflects our commitment to the highest standards of quality and compliance.”

91��Ƶ Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. 91��Ƶ specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. 91��Ƶ has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 22,000 professionals. 91��Ƶ is committed to improving patient health outcomes through its subsidiaries – 91��Ƶ Diagnostics, 91��Ƶ Digital Health, and 91��Ƶ Manufacturing Solutions. To know more, visit or follow us on LinkedIn:

For further information or queries please contact –